Amgen (AMGN) Cash from Investing Activities (2009 - 2026)

Amgen's Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$716.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 60.18% year-over-year to -$716.0 million; the TTM figure through Mar 2026 stood at -$2.2 billion (down 73.35% YoY), while the FY2025 annual figure was -$1.9 billion, down 85.76% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$716.0 million, down from -$693.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $1.4 billion in Q1 2023, with the low at -$27.1 billion in Q4 2023.
• The 5-year median for Cash from Investing Activities is -$389.0 million (2025), against an average of -$2.1 billion.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities plunged 1410.0% in 2022, then surged 1323.42% in 2023.
• Amgen's Cash from Investing Activities stood at -$3.5 billion in 2022, then plunged by 679.99% to -$27.1 billion in 2023, then soared by 98.52% to -$402.0 million in 2024, then tumbled by 72.39% to -$693.0 million in 2025, then slipped by 3.32% to -$716.0 million in 2026.
• Business Quant data shows AMGN's Cash from Investing Activities at -$716.0 million in Q1 2026, -$693.0 million in Q4 2025, and -$414.0 million in Q3 2025.